Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Condition(s):NSCLCLast Updated:November 15, 2019Unknown status
Hide Studies Not Open or Pending
Condition(s):NSCLCLast Updated:November 15, 2019Unknown status
Condition(s):Gaucher DiseaseLast Updated:February 1, 2022Completed
Condition(s):Acute Myelogenous LeukemiaLast Updated:March 3, 2020Completed
Condition(s):Chronic Hepatitis CLast Updated:April 16, 2015Completed
Condition(s):Hepatitis C Virus InfectionLast Updated:November 16, 2018Completed
Condition(s):Hepatitis C, ChronicLast Updated:August 29, 2023Completed
Condition(s):HIV-1/HBV Co-InfectionLast Updated:March 19, 2024Completed
Condition(s):Hepatitis C; HIV-1-infection; Liver DiseasesLast Updated:February 4, 2022Completed
Condition(s):Chronic Hepatitis C(CHC)Last Updated:October 26, 2018Completed
Condition(s):Post Menopausal OsteoporosisLast Updated:March 9, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.